The hypothalamic melanocortin-4 receptor (MC4R) is a constituent of an important pathway regulating food intake and energy expenditure. We produced a monoclonal antibody (mAb) directed against the N-terminal domain of the MC4R and evaluated its potential as a possible therapeutic agent. This mAb (1E8a) showed specific binding to the MC4R in HEK-293 cells expressing the human MC4R and blocked the activity of the MC4R under basal conditions and after stimulation with α-melanocyte stimulating hormone (α-MSH). The inverse agonist action of agouti-related protein (AgRP) was significantly enhanced in the presence of mAb 1E8a. After a single intracerebroventricular (i.c.v.) injection into the third ventricle mAb 1E8a (1µg) increased 24h-food intake in rats. After 7 days of continuous i.c.v. administration mAb 1E8a increased food intake, body weight and fat pad weights and induced hyperglycemia. Because the complete mAb was ineffective after intravenous (i.v.) injection, we produced single chain variable fragments (scFv) derived from mAb 1E8a. In pharmacokinetic studies it was demonstrated that these scFv crossed the blood-brain barrier and reached the hypothalamus. Consequently, the scFv 1E8a increased significantly food intake and body weight in rats after i.v. administration (300µg/kg). The pharmacological profile of mAb 1E8a and the fact that its scFv fragment was active after peripheral administration suggest that derivatives of anti-MC4R mAbs may be useful in the treatment of patients with anorexia or cachexia.
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Introduction Antibodies (Abs) as therapeutic agents are currently receiving renewed interest in experimental and clinical medicine. Their selectivity, potency and efficacy at various targets have made them successful drugs in different indications, mainly cancer and autoimmune disorders (Kornbluth, 1998; Schuna and Megeff, 2000; Bohen et al., 2003) . In previous studies in rats (Peter et al., 2007; Hofbauer et al., 2008) we used active and passive immunization to stimulate appetite by inhibiting the activity of the central melanocortin-4 receptor (MC4R).
The MC4R is part of an important central pathway of appetite regulation (Cowley, 2003; Ellacott and Cone, 2004; Adan et al., 2006) . Its stimulation leads to an anorexigenic response, i.e. a decrease in appetite and food intake. Conversely, its blockade induces an orexigenic response, i.e. an increase in appetite and food intake. Blockade of the MC4R has been demonstrated to be effective in preventing anorexia and the concomitant loss of fat and lean body mass in rodent models of tumour-induced cachexia (Scarlett and Marks, 2005; DeBoer and Marks, 2006; Nicholson et al., 2006) .
In all of our immunization experiments the N-terminal (NT) domain of the MC4R was used as an antigen because it is known to be essential for the constitutive activity of this receptor (Srinivasan et al., 2004 ). We could demonstrate that active immunization of rats against a 16-amino acid sequence of the NT domain resulted in a mild form of obesity and insulin resistance (Peter et al., 2007) . Furthermore, immunization of rats against the NT peptide prevented the decrease of body weight and the loss of appetite in an acute model of anorexia induced by the intraperitoneal (i.p.) application of lipopolysaccharide (Hofbauer et JPET #163279 5 al., 2008) . In a series of in vitro experiments we demonstrated that anti-MC4R Abs purified from the plasma of immunized rats acted as inverse agonists in the absence and as noncompetitive antagonists in the presence of an MC4R agonist (Peter et al., 2007) . Finally it could be shown that the passive transfer of purified polyclonal Abs from immunized rats by intracerebroventricular (i.c.v.) injection into the third ventricle of non-pretreated rats induced an increase in their food intake (Peter et al., 2007) .
In the present study, we produced and characterized a monoclonal antibody (mAb) targeting the NT sequence of the MC4R and explored its therapeutic potential. This mAb (1E8a) acted in vitro as an inverse agonist and as a non-competitive antagonist. In vivo, mAb 1E8a increased food intake in rats after acute and chronic (i.c.v.) administration but was not effective after intravenous (i.v.) administration. In order to improve penetration across the blood-brain barrier, recombinant single chain variable fragments (scFv) were produced and evaluated in vitro and in vivo. They also acted as inverse agonists and noncompetitive antagonists and increased food intake after i.v. administration. To our knowledge, this is the first report on a pharmacologically active mAb against the MC4R and its scFv. By virtue of their pharmacological profile and their pharmacokinetic properties these agents could represent lead molecules for the development of therapies for patients with anorexia or cachexia.
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Methods

Production of monoclonal antibodies
A peptides corresponding to the NT domain of the MC4R (KTSLHLWNRSSHGLHG, residues 11-25 of the MC4R) was used as antigen. The NT peptide share the sequence of the rat MC4R (rMC4R) and human MC4R (hMC4R) isoform from residues 2 to 15. NT3 peptide (ASNRSGSGFCEQVFIKPEV, residues 26-44 of the MC3R) was synthesized as previously described (Peter et al., 2007) . C57BL/6 mice were immunized with 25µg of the free NT peptide emulsified in complete Freund's adjuvant and injected subcutaneously (s.c.). Four weeks later a booster injection of 25µg in incomplete Freund's adjuvant was given. Another four weeks later 10µg peptide dissolved in NaCl 0.9% was injected i.v. three days before harvesting the spleen cells for fusion. Fusion was performed with polyethylene glycol 1500 (Sigma, Saint Louis, MO, USA) at a ratio of 2 splenocytes for 1 SP2O myeloma cell. Hybridomas were cultivated in 96 well plates precoated with peritoneal macrophages of C57BL/6 mice 1000 cells/well. 5x10 5 cells
were distributed per well in Isocoves Modified Dulbecco's Medium (IMDM) supplemented with 10% heat inactivated fetal calf serum, 200mM glutamine, 100mM sodium pyruvate, 1%
penicillin streptomycin (Omnilab, Mettmenstetten, Switzerland), 3% Hypoxanthine, Aminopterine, Thymidine (HAT, Gibco, Lucerne, Switzerland) in a humidified incubator at 37°C under an atmosphere of 5% CO 2 . Secreting clones were screened by enzyme immunoassay and subcloned by limiting dilution (Oi et al., 1980) . Reactions were stopped after 15 min by the addition of HCl (1N). Optical density (OD) was measured at 450nm by using a microplate reader Multiskan RC (Labsystem, Haverhill, MA, USA).
Isotyping and purification
The isotype of the selected mAbs was determined using MonoAbiD kit according to manufacturer's instructions (Zymed Lab, Paris, France). The anti-NT mAbs were affinitypurified on activated CNBr-Sepharose 4B column (Amersham Biosciences, Uppsala, Sweden) with NT peptide coupled via the N-terminus according to manufacturer's instructions. Culture supernatants were loaded on the column at 4 o C. The mAbs were eluted with 0.2M glycine pH 2.7, collected in tubes containing 1M Tris buffer (pH 8.0), subsequently dialyzed against PBS overnight at 4°C and finally stored at -20°C.
This article has not been copyedited and formatted. The final version may differ from this version. Dawley rats were prepared as described previously (Peter et al., 2005) . MC4R membrane preparations (50µg) were incubated with purified mAb 1E8a (25μg) or mAb 2G2 (25µg) overnight at 4°C. The mixture was immunoprecipitated with 25µl of protein A/G agarose.
The immunoprecipitated samples were loaded on a 10% polyacrylamide gel and transferred onto nitrocellulose membranes. The presence of MC4R was detected by using polyclonal anti-MC4R Abs (Abcam, Cambridge, UK) and the presence of MC3R using polyclonal anti-MC3R Abs (Abcam) in the standard procedure described in the one-Step
TM
Complete IP-Western kit (Genscript, Piscataway, NJ, USA).
Inhibition expreriments
Purified mAb 1E8a (25µg) was preincubated overnight at 4°C in the presence or absence of increasing concentrations of the NT peptide (32nM -100μM). MC4R membrane preparations from HEK-293 cells stably transfected with the hMC4R (50µg) were incubated with the mAb 1E8a/NT peptide mixture overnight at 4°C. The mixtures were immunoprecipitated with 25µl of protein A/G agarose. The immunoprecipitated samples were loaded on a 10% polyacrylamide gel and transferred onto nitrocellulose membranes.
The presence of MC4R was detected by using polyclonal anti-MC4R Abs (Abcam) in the standard procedure described in the one-Step TM Complete IP-Western kit (Genscript). The western blot films were digitalized and resulting images were quantified using scion Image Beta 4.03.02 (downloaded from www.scioncorp.com). Inhibition percent of the interaction of the mAb 1E8a with the hMC4R was calculated as follows: 1-(OD [NT] /OD (without NT) )x100
where OD [NT] is the optical density of the band corresponding to the hMC4R for a given JPET #163279 9 concentration of NT peptide and OD (without NT) is the optical density of the band corresponding to the hMC4R without NT peptide.
Surface plasmon resonance
Assays were performed in the BIACORE 3000 system as described previously (Peter et al., 2007) . Kinetic parameters of the interaction between NT peptide and anti-MC4R mAbs were measured at 25°C in two series of experiments: first, 5 different concentrations (0.25 -4µM) of purified mAb 1E8a were injected at a flow rate of 30µl/min for 300sec on the immobilised NT peptide or NT3 peptide as control followed by a dissociation phase of 400sec. Subsequently, 5 different concentrations (0.125 -1µM) of purified mAb 2G2 were injected at a flow rate of 30µl/min for 300sec on the immobilised NT peptides followed by a dissociation phase of 400sec. The kinetic parameters were calculated using BIA evaluation software 4.1 (Biacore, Uppsala, Sweden Immunocytofluorescence HEK-293 cells expressing hMC4R or hMC3R were fixed for 5min with 2% paraformaldehyde in PBS. Slides were saturated with PBS supplemented with 5% non-fat dried milk. mAbs 2G2 or 1E8a (50µg/ml) were applied on cells for 1h at RT. After 3 washes with PBS, goat anti-mouse alexa conjugated (1/500) (Molecular Probes, Junction City, OR, USA) was allowed to react with the fixed primary antibody for 1h at RT. 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) (1µg/ml, Molecular Probes) was used for nuclear staining. The same magnification (40x) and exposure time (500msec) was used for each slide.
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Cloning of cDNA encoding the variable domain of the mAbs
Total RNA was prepared from 10 7 freshly subcloned hybridoma cells using the RNAnow kit (Biogentex Inc., Seabrook, TX, USA) and first strand cDNA was synthesized using 
Expression of scFvs
Escherichia Coli Rosetta bacterias transformed with pET22b(+)-1E8a or pET22b(+)-2G2
were grown in 500ml of medium 2xYT (bactotryptone 1.6%, bactoyeast extract 1%, NaCl 0.5%, pH 7.0) containing ampicilline 0.15mM (Applichem, Darmstadt, Germany) and chloramphenicol 0.1mM (Gerbu Biotechnik, Gaiberg, Germany) until an OD 600nm of 0.6 at 37°C with agitation at 200rpm. The expression of scFv was induced by adding 1mM IPTG (Applichem) at RT during 4h.
Periplasmic extraction
500ml of bacteria cultures were centrifuged (10min, 10,000g, 4°C) and the pellet was resuspended in 200ml of TES (Tris 30mM, EDTA 1mM, sucrose 2%, pH 8.5). After centrifugation (10min, 10,000g, 4°C), the pellet was resuspended in 50ml MgSO 4 5mM.
After a last centrifugation (10min, 10,000g, 4°C) the supernatant corresponding to the periplasmic extract (PE) was collected. This PE was dialyzed in wash buffer NiNTA (imidazole 20mM, Na 2 HPO 4 50mM, NaCl 300mM, pH 8.0) overnight at 4°C.
Purification of scFv
The scFvs were purified from the PE on NiNTA columns according to the manufacturer's instruction (Qiagen). After elution, purified scFvs were dialysed in PBS (Na 2 HPO 4 10mM, NaCl 150mM, KCl 27mM, pH 7.4) overnight at 4°C. The scFvs were then purified by Quality and purity of the purified scFv fractions were assessed by SDS-PAGE analysis using 12.5% acrylamide gels followed by staining with Coomassie brilliant blue (Biorad) and western blot. For western blot analysis, the proteins were transferred from the gels onto a nitrocellulose transfer membrane a mini trans-blot system ( 
Radioactive labeling and purification
The scFv 1E8a was radioactively labeled with 
Pharmacokinetics of brain uptake
Male CD-1 mice were anesthetized with urethane. All animal studies were done in accordance with international standards and under protocols approved by the local animal use committee. The blood-to-brain unidirectional influx rate (Ki, in units of μ l/g-min) was calculated by multiple-time regression analysis Patlak et al., 1983) .
In brief, the right jugular vein and the left carotid artery were exposed. At t = 0, 0.2ml of 
and Cp is the level of radioactivity in serum and Cpt is the level of radioactivity in serum at time t. Expt values correct for the clearance of the test substance from the blood so that the greater the clearance from blood the greater the difference between Expt and t.
Without this correction, Ki would be overestimated. Brain/serum ratios for whole brain were calculated by summing the brain region values for radioactivity and weight. The slope of the linear portion of the relation between brain/serum ratios and Expt measures Ki and the intercept of the linearity measures Vi (µl.g), the initial volume of distribution in brain.
In other mice, I-Alb was included in the i.v. injection. The percent of the injected dose taken up per g of brain (%Inj/g) was calculated as follows:
where A is the brain/serum ratio for I-scFv and B is the ratio for I-Alb.
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Acid precipitation
To determine whether the radioactivity in brain and serum at various times represented intact I-scFv, we performed acid precipitation on radioactivity obtained at 30min and 4h after i.v. injection. Whole blood was centrifuged and 50µl of the resulting serum added to 100µl of LR-BSA and then to 100µl of 30% trichloroacetic acid. The sample was vigorously mixed and centrifuged at 5400g for 15min at 4°C. The resultant supernatant and precipitate were separated and counted and the results expressed as the percent of total counts that were precipitated. Brains were homogenized in a glass homogenizer in 3ml of LR-BSA and then centrifuged at 5400g for 10min at 4°C. An aliquot of 0.5ml of the supernatant was added to 0.5ml of 30% trichloroacetic acid, the sample vigorously mixed, and then centrifuged at 5400g for 10min at 4 °C. The supernatant and precipitate were separated and counted and the results expressed as the percent of total counts that precipitated. To correct for any degradation that might have occurred during the processing for acid precipitation, we added I-scFv to non-radioactive arterial whole blood or to whole brain. These samples were then processed as above and the percent of total counts that were precipitated determined. The mean of 2 processing controls was 96% for serum and 89% for brain. The values for the biological samples were divided by the value of the processing control and multiplied by 100 to give the reported result.
Capillary depletion
Capillary depletion as modified for use in the mouse (Triguero et al., 1990; Gutierrez et al., 1993 ) was used to determine the degree to which I-scFv was sequestered by the vascular bed of the brain. Mice were anesthetized with urethane and given an injection into the jugular vein of 0.2ml saline containing 10 6 cpm of I-scFv and 10 6 cpm I-Alb. After 2h, arterial D-glucose adjusted to pH 7.4). Dextran solution was added to the homogenate to a final concentration of 26%. An aliquot was centrifuged at 5400g for 15min at 4ºC in a swinging bucket rotor. The pellet containing the brain microvessels and the supernatant containing the brain parenchyma were carefully separated. Results were expressed as capillary/serum and parenchyma/serum ratios. Values for I-Alb were subtracted from those for I-scFv to yield values corrected for residual vascular contamination and blood-brain barrier leakage.
I.c.v. and i.v. administration
Male Sprague-Dawley rats (275 to 325g) were anesthetized with isoflurane in medicinal oxygen (4% for induction and 2% for maintenance of anesthesia). A stainless steel cannula (26 gauge, 10mm long) was implanted into the third cerebral ventricle using the following coordinates, relative to the Bregma: -2.3mm anteroposterior, 0mm lateral to the midline, and continuously recorded during the following 3 days using an automatic food intake apparatus (TSE Systems, Bad Homburg, Germany) at one hour intervals.
Osmotic minipumps (model 2002) (Alza Corp., Charles River Laboratories Inc., SaintAubin-les-Elbeuf, France) were filled with mAbs 1E8a or 2G2 calculated to deliver 1μg/day during 7 days. One week after the angiotensin II test the pumps were implanted dorsally under the skin under isoflurane anesthesia and immediately connected to the i.c.v. cannula via a tube prefilled with mAbs to ensure an immediate delivery. Body weight and food intake were monitored during the treatment by using an automatic food intake apparatus (TSE Systems, Bad Homburg, Germany).
In the experiments with i.v. administration, purified mAbs 1E8a or 2G2 and scFvs 1E8a and 2G2 were injected into the tail vein of rats at 9:00 am under mild isoflurane anesthesia at a dose of 300µg/kg. Following the injection of scFv or mAb, food intake was continuously recorded using an automatic food intake apparatus (TSE Systems) at one hour intervals for 3 days.
Data analysis
All data are expressed as mean ± SD or SEM as indicated. Data were analysed by two-way ANOVA repeated measures with Bonferroni post-hoc test or by Student t-test using Graph pad Prism 4 software. For the cAMP concentration-response experiments, the best fitting curves were compared for their minimum, maximum and EC 50 using F-test. Ki and EC 50
were calculated using Graph pad Prism 4 software. 
Results
Selection of mAbs and selectivity of mAb 1E8a
The mouse serum used for hybridoma production showed a pronounced response against the immunogenic peptide derived from the N-terminus of the MC4R but not against the corresponding peptide derived from the N-terminus part of the MC3R. Although the polyclonal response was high, only 10 clones were viable until subcloning and amplification 
Pharmacological activity of 1E8a and 2G2 mAbs in vitro
When HEK-293 cells transfected with the hMC4R were exposed to increasing concentrations of mAb 2G2 (1pM -0.1µM), no decrease in cAMP formation was measured (Figure 2a) . Conversely, when HEK-293 cells were exposed to increasing concentrations of mAb 1E8a (1pM -0.1µM) cAMP formation was decreased in a concentration-dependent manner by up to 40% (EC 50 of 2.1x10 -12 M) (Figure 2c ).
The presence of 100nM of mAb 2G2 did not change the concentration response curve of α -MSH (Figure 2b ) but the presence of 100nM of mAb 1E8a significantly (p<0.001, F-test) reduced the maximum effect of α -MSH (Figure 2d ).
When HEK-293 cells transfected with the hMC4R were exposed to increasing concentrations of AgRP (1pM -0.1µM) a decrease in cAMP formation was measured (Figure 2e ). In the presence of 100nM of mAb 1E8a, a leftward shift of the AgRP concentration-response curve was observed.
Receptor internalization
The presence of mAb 1E8a (100nM) did not influence the internalization of the MC4R expressed at the surface of HEK cells (Figure 3 ).
Pharmacological activity of mAbs 1E8a and 2G2 in vivo
Rats which received an injection of 1 µg of mAb 1E8a into the third ventricle ingested 24% more food in 24h than rats which received mAb 2G2 or BSA as controls (Figure 4a ). The body weight of rats which received mAb 1E8a was increased whereas body weight was reduced in rats which received either mAb 2G2 or BSA (Figure 4b 1E8a was significantly less reduced than in control rats (Figure 4d ). After 7 days of continuous i.c.v. infusion, a non-significant increase of the fasting glycemia ( Figure 4e ) and a significant increase in fat pads weight were observed (Figure 4f ).
Variable domain cloning and scFv expression
The scFv-encoding genes derived from the variable regions (V H and V L linked together via a short linker (G 4 S) 3 of the mAb 1E8a and mAb 2G2, with addition of a C-terminal six-His tag encoding sequence), were inserted in frame with the PelB sequence into the pET22b expression vector. The sequence of the single chain construction is represented in Figure   5 . We confirmed that the cloned VL gene did not correspond to the aberrant kappa transcript of the sp20 hybridomas (Carroll et al., 1988) . The plasmid pET-scFv 1E8a or pET-scFv 2G2 was cloned into the Rosetta Escherichia Coli strain and the recombinant protein was expressed and exported to the bacterial periplasm by its leader sequence PelB (Lei et al., 1987) . The scFv 1E8a and scFv 2G2 were purified and concentrated by IMAC chromatography and repurified by immunoabsorption to get rid of the not correctly folded inactive recombinant proteins (Peter et al., 2003) (Figure 6 ). The affinity of these scFv for the NT peptide was assessed by surface plasmon resonance. A K D of 7.8x10 -7 M for the scFv 1E8a and 2.4x10 -7 M for the scFv 2G2 was calculated.
Pharmacological effect of the scFv 1E8a and 2G2 in vitro
When HEK-293 cells transfected with the hMC4R were exposed to increasing concentrations of scFv 2G2 (1pM to 0.1µM), no decrease in cAMP formation was measured ( Figure 7a) . Conversely, when HEK-293 were exposed to increasing concentrations of scFv 1E8a (1pM to 0.1µM) cAMP formation decreased in a concentration-dependent manner by up to 40% (Figure 7c ). 
Pharmacokinetics of scFv 1E8a
When iodinated scFv (I-scFv) was injected i.v. and its clearance from blood calculated, the relation between log(%Inj/ml) and time was highly significant (r=0.788, n=20, p<0.001) with a half-life of 84.6 min and a distribution volume (Vd) of 2.15 ml. This shows that I-scFv distribution was limited to the vascular space. 
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In capillary depletion experiments, it was found that the capillary/serum ratio was 0.57±0.05
µl/g and that the parenchymal/serum ratio was 1.03±0.17μl/g. This showed that the majority of I-scFv taken up by the blood-brain barrier was not sequestered by the capillary bed, but entered the brain parenchymal space.
Pharmacological activity of scFvs 1E8a and 2G2 in vivo
1µg of purified scFv 1E8a and scFv 2G2 was injected into the third ventricle of rats. Rats which received scFv 1E8a ingested 45% more food in 24 h than rats which received scFv 2G2 ( Figure 9a ). The body weight of rats which received scFv 1E8a was significantly less decreased than that of rats that received scFv 2G2 (Figure 9a ).
Purified scFv 1E8a and scFv 2G2 were injected (300µg/kg) i.v. in rats. Rats which received scFv 1E8a ingested 33% more food in 24h than rats which received scFv 2G2 (Figure 9b ).
The body weight of rats which received scFv 1E8a was unchanged whereas body weight was reduced in rats which received scFv 2G2 (Figure 9b ).
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Discussion
The MC4R is a key receptor for the regulation of food intake and energy expenditure. Its dysfunction leads to severe obesity in rodents and humans (Ste Marie et al., 2000; Farooqi et al., 2003) . Conversely, its over-activation in chronic diseases such as cancer which is probably caused by high levels of circulating cytokines (Huang et al., 1999) leads to cachexia (Marks and Cone, 2001) . Blockade of the MC4R in rodent models of cachexia showed a significant increase in lean body mass (Nicholson et al., 2006) . Moreover, rats immunized against the NT domain of the MC4R were resistant to lipopolysaccharideinduced anorexia (Hofbauer et al., 2008) .
In a previous study we demonstrated that immunization against the N-terminus of the MC4R in rats led to the generation of pharmacologically active Abs which acted as inverse agonists and non-competitive antagonists (Peter et al., 2007) . In the present study, we characterised the pharmacological properties of a mAb (1E8a) against this peptide sequence of the NT domain in vitro and in vivo. Another mAb (2G2) which recognized the NT peptide but not the corresponding sequence in the native receptor served as a control throughout our experiments.
The binding properties of mAbs 1E8a and 2G2 were studied in two different in vitro experiments. By using immunocytofluorescence in HEK293 cells overexpressing the hMC3R or hMC4R, binding to the native form of the hMC4R and subtype selectivity was assessed. The mAb 1E8a bound to the hMC4R but not to the hMC3R on the cell surface, a result which was not unexpected because the N-terminal sequences of the MC3R and MC4R subtypes show a low degree of homology (Gantz et al., 1993) . In general, the sequences of extracellular domains are less well conserved than those of transmembrane domains and are therefore suitable targets for a subtype-selective pharmacological approach (Mirzadegan et al., 2003) .
The mAb 2G2 showed no interaction with either hMC3R or hMC4R at the cell surface.
These results are consistent with our immunoprecipitation experiments which indicated that mAb 1E8a bound to hMC4R and rMC4R with high affinity whereas the mAb 2G2 interacted only with the NT peptide but not with the corresponding sequence in the native MC4R. A specific interaction of mAb 1E8a with the MC4R was supported by the observation that increasing concentrations of the NT peptide reduced the binding of mAb 1E8a with a Ki in the µM range. As compared with the Kd of the mAb 1E8a/NT peptide binding, which is in the nM range, this Ki indicated an better binding of mAb 1E8a to the native conformation of the receptor than to the NT peptide.
The affinity of the mAb 1E8a and the mAb 2G2 for the NT peptide were in the same range M, respectively). They are relatively high for an IgM isotype but other high affinity IgM mAbs have been previously described (Ballard et al., 1983; Suenaga and Abdou, 1992; Cao et al., 2004) . The small difference between the affinity of mAbs 1E8a and 2G2 cannot explain why the latter did not interact with the MC4R. This might indicate that the paratope of mAb 2G2 interacted with a conformation of the NT peptide that the intact receptor is unable to adopt. In contrast, mAb 1E8a is able to recognize a common structure shared by the NT peptide and the NT domain in the native MC4R.
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The pharmacological properties of mAb 1E8a were assessed by using adenylyl cyclase assays in HEK-293 cells overexpressing the hMC4R. The mAb 1E8a behaved as an inverse agonist and decreased basal activity by 40% with an EC 50 in the pM range. It behaved as a non-competitive antagonist in the presence of α -MSH and decreased the maximum efficacy of this agonist by 20%. A pattern of inverse agonism combined with noncompetitive antagonism has been described for other Abs at G-protein coupled receptors (Peter et al., 2003; Peter et al., 2004; Peter et al., 2007) . The mAb 2G2 did neither affect the constitutive activity of the MC4R nor the concentration-response curve of α -MSH.
In order to find out whether the in vitro effects of mAb 1E8a translated into efficacy in vivo purified mAb 1E8a was administered into the third ventricle of rats. The mAb 2G2 served as a control. When given at the beginning of the light phase mAb 1E8a increased 24h food intake by approximately 25%. This acute effect is not too different from that obtained with SHU 9119, a peptidic MC3/MC4R antagonist (Obici et al., 2001; Peter et al., 2007) .
However, the main effects on food intake were seen during the dark phase. This finding is at variance with the fact that MC4R tone is highest during the light phase when satiety prevails. The fact that AgRP expression is higher during the dark phase (Lu et al., 2002) together with our observation that mAb 1E8a strongly enhanced the effects of AgRP in vitro might offer an explanation for this result.
When mAb 1E8a was continuously infused via osmotic minipumps into the third ventricle in rats, a 70% increase of food intake as compared with controls was recorded during the first 24h. This difference is much more pronounced than that seen after i. At the end of the 7-day treatment period with mAb 1E8a we observed a trend for an increase in glycemia and a significant increase in fat pads weight. Similar findings have been reported in MC4R knock-out mice (Fan et al., 2000) , in rats after central administration of antisense oligonucleotides against the MC4R (Obici et al., 2001 ) and in rats immunized with the NT peptide of the MC4R (Peter et al., 2007; Hofbauer et al., 2008) .
No effects on food intake were seen after single i.v. administration of mAb 1E8a in a dose Pharmacokinetic studies were performed to further address the issue of brain penetration.
Uptake of I-scFv was uniform across several brain regions and exceeded that of the vascular marker albumin. This suggests a mechanism of uptake other than entry by way of extracellular pathways (Broadwell and Sofroniew, 1993) , the mechanism proposed for IgG (Banks et al., 2002; Banks et al., 2005) and IgM molecules (Banks et al., 2007) . Capillary depletion showed that about 1/3 of the I-scFv retained by brain was sequestered by brain endothelial cells, while about 2/3 were located in brain parenchyma. This sequestration by capillaries also suggests that a transcytotic pathway across the blood-brain barrier is more likely than leakage into brain by the extracellular pathways.
A long half-life from brain and enzymatic resistance contributed to brain accumulation as well. We calculated that by 2h, about 0.2 percent of the i.v. injected dose had been taken up by whole brain. However, we did not correct for degradation in brain with time, so the value may be 30-50% lower than this. This would still produce brain levels that are similar to or greater than those seen with other proteins which are centrally active (Banks et al., 1991; Banks et al., 1993; Banks et al., 1996) and therefore sufficient for a pharmacological effect. However, receptor binding studies would have been needed to clearly demonstrate that the scFv fragment reached its presumed hypothalamic site of action at concentrations which were biologically active.
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In this paper we report for the first time that an anti-MC4R mAb and its scFv derivative are able to modulate the MC4R activity in vitro and in vivo. The scFv 1E8a crossed the bloodbrain barrier in amounts sufficient to increase food intake after i.v. administration in rats.
Such molecules might therefore represent a starting point for the development of new therapies for patients with anorexia and cachexia.
